This Article Full Text Full Text (PDF) Other Versions of this Article: JVI.02395-06v1 81/8/3992    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Langley, D. R. Articles by Tenney, D. J. Search for Related Content PubMed PubMed Citation Articles by Langley, D. R. Articles by Tenney, D. J.

 Previous Article  |  Next Article 

Journal of Virology, April 2007, p. 3992-4001, Vol. 81, No. 8
0022-538X/07/$08.00+0     doi:10.1128/JVI.02395-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Inhibition of Hepatitis B Virus Polymerase by Entecavir

Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06443

Received 1 November 2006/ Accepted 20 December 2006

Entecavir (ETV; Baraclude) is a novel deoxyguanosine analog with activity against hepatitis B virus (HBV). ETV differs from the other nucleoside/tide reverse transcriptase inhibitors approved for HBV therapy, lamivudine (LVD) and adefovir (ADV), in several ways: ETV is >100-fold more potent against HBV in culture and, at concentrations below 1 µM, displays no significant activity against human immunodeficiency virus (HIV). Additionally, while LVD and ADV are obligate DNA chain terminators, ETV halts HBV DNA elongation after incorporating a few additional bases. Three-dimensional homology models of the catalytic center of the HBV reverse transcriptase (RT)-DNA-deoxynucleoside triphosphate (dNTP) complex, based on the HIV RT-DNA structure, were used with in vitro enzyme kinetic studies to examine the mechanism of action of ETV against HBV RT. A novel hydrophobic pocket in the rear of the RT dNTP binding site that accommodates the exocyclic alkene moiety of ETV was predicted, establishing a basis for the superior potency observed experimentally. HBV DNA chain termination by ETV was accomplished through disfavored energy requirements as well as steric constraints during subsequent nucleotide addition. Validation of the model was accomplished through modeling of LVD resistance substitutions, which caused an eightfold decrease in ETV susceptibility and were predicted to reduce, but not eliminate, the ETV-binding pocket, in agreement with experimental observations. ADV resistance changes did not affect the ETV docking model, also agreeing with experimental results. Overall, these studies explain the potency, mechanism, and cross-resistance profile of ETV against HBV and account for the successful treatment of naive and LVD- or ADV-experienced chronic HBV patients.

Published ahead of print on 31 January 2007.

This article has been cited by other articles:

• Domaoal, R. A., McMahon, M., Thio, C. L., Bailey, C. M., Tirado-Rives, J., Obikhod, A., Detorio, M., Rapp, K. L., Siliciano, R. F., Schinazi, R. F., Anderson, K. S. (2008). Pre-steady-state Kinetic Studies Establish Entecavir 5'-Triphosphate as a Substrate for HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 5452-5459 [Abstract] [Full Text]  
• Mazzucco, C. E., Hamatake, R. K., Colonno, R. J., Tenney, D. J. (2008). Entecavir for Treatment of Hepatitis B Virus Displays No In Vitro Mitochondrial Toxicity or DNA Polymerase Gamma Inhibition. Antimicrob. Agents Chemother. 52: 598-605 [Abstract] [Full Text]